This is an aggregated industry headline. Read the full story at BioPharma Dive →
Remix to go public in reverse merger with once high-flying Passage Bio
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.
By BioPharma Dive
· Jun 25, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
BeOne Medicines has extended its relationship with Blood Cancer United, committing $5 million over three years…
The WeekFierceBiotech ↗
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered discovery pl…
The WeekBriefing
Otsuka’s ADHD drug candidate met its Phase 3b endpoint in adults with comorbid anxiety, adding key data weeks …